Bluejay Diagnostics filings document the company’s medical diagnostics business, Nasdaq-listed common stock, and disclosures tied to development of the Symphony™ near-patient testing platform. Form 8-K reports cover corporate updates, financial condition items, Regulation FD disclosures, SYMON clinical-study updates, conference-related product disclosures, manufacturing readiness, and capitalization matters involving warrants and private placements.
The company’s proxy materials describe annual meeting proposals, voting procedures, board and governance matters, and stockholder approval topics. Bluejay’s filings also identify it as an emerging growth company and include formal disclosures on material agreements, registered securities, risk-relevant development activities, and capital-structure changes such as reverse stock splits and warrant exercises.
Bluejay Diagnostics, Inc. reported an update for the quarter ended June 30, 2026, highlighting progress on its Symphony™ platform and lead Symphony IL-6 test while strengthening its balance sheet. The company completed targeted enrollment of 750 hospital patients in the SYMON-II pivotal clinical validation study and is advancing analytical and clinical validation work intended to support a future FDA 510(k) submission.
At June 30, 2026, Bluejay held approximately $9.6 million in cash and cash equivalents, up from approximately $5.2 million at December 31, 2025. During the first half of 2026, it generated about $7.7 million of net cash from financing activities, including roughly $7.6 million of net proceeds from a June 2026 private placement. Management estimates current cash resources will fund operations through the second quarter of 2027, with capital allocation focused on manufacturing readiness, regulatory submission activities, and commercialization planning for Symphony. The Symphony platform remains an investigational device and will require U.S. Food and Drug Administration authorization before it can be marketed as a diagnostic product in the United States.
Bluejay Diagnostics, Inc. is a development‑stage medical diagnostics company advancing its Symphony platform and first IL‑6 test for sepsis, with clinical and regulatory efforts focused on supporting a planned 510(k) submission to the FDA, currently targeted for the first half of 2027, subject to successful analytical and clinical validation.
For the six months ended June 30, 2026, the company reported a net loss of $4,243,254, compared with $3,821,039 a year earlier, driven mainly by higher clinical development spending; research and development expenses were $2,249,643 and general and administrative expenses were $2,038,312.
Cash and cash equivalents were $9,598,916 and current liabilities were $2,116,641 as of June 30, 2026, with an accumulated deficit of $45,760,521 and negative operating cash flow of $3,088,556 for the six‑month period, leading management to state that substantial doubt exists about its ability to continue as a going concern. The company raised gross proceeds of approximately $8.5 million in a June 2026 private placement and $125,000 in a March 2026 insider financing, and estimates existing cash will fund operations through the second quarter of 2027 while it seeks an additional $10.0–$14.0 million of capital and works to maintain Nasdaq listing compliance.
Bluejay Diagnostics, Inc. reports successful completion of patient enrollment in its SYMON-II multicenter clinical validation study, reaching its target of 750 sepsis patients ahead of plan. SYMON-II is a pivotal study evaluating the Symphony IL-6 test for early assessment of 28-day all-cause mortality risk in ICU sepsis patients.
Preliminary observations show an approximately 17% 28-day mortality rate in the enrolled population, providing a large dataset to assess the prognostic utility of IL-6. The company states that SYMON-II is intended to validate earlier findings and is part of a clinical program it plans to use to support a future FDA 510(k) application and potential commercialization of its investigational Symphony rapid, near-patient diagnostic platform.
Bank of America Corporation, Bank of America N.A. and BofA Securities, Inc. jointly state that their beneficial ownership in Bluejay Diagnostics, Inc. has fallen below 10 percent, so they are no longer treated as Section 16 ten percent owners.
Bluejay Diagnostics, Inc. received an initial insider ownership report from Bank of America Corporation and its subsidiaries Bank of America N.A. and BofA Securities, Inc. The statement lists 8 shares of common stock as indirectly beneficially owned through these subsidiaries, and notes they may be deemed to have temporarily held voting and dispositive power over additional shares as a result of short-term stock borrowings.
HRT Financial LP, a ten percent owner of Bluejay Diagnostics, Inc., reported mixed trading in the company’s common stock. On July 9, 2026, it executed an open-market purchase of 64,047 shares at $1.51 per share. On July 10, 2026, it made an open-market sale of 34,938 shares at $1.40 per share. After these transactions, HRT Financial LP directly held 92,055 shares of Bluejay Diagnostics common stock, reflecting a net increase of 29,109 shares over the two days.
HRT Financial LP filed an initial statement of beneficial ownership as a ten percent owner of Bluejay Diagnostics, Inc.. The filing reports direct ownership of 126,993 shares of Common Stock as of July 9, 2026, with no specific buy or sell transaction disclosed.
Bluejay Diagnostics, Inc. received a Form 4 filing from three related institutional holders: BANK OF AMERICA CORP /DE/, BOFA SECURITIES, INC., and BANK OF AMERICA NA. Each is identified as a ten percent owner of Bluejay Diagnostics, but this filing does not list any specific share transactions or option exercises, functioning instead as a beneficial ownership report.
Bank of America Corporation, together with subsidiaries Bank of America N.A. and BofA Securities, Inc., filed an initial ownership report for Bluejay Diagnostics, Inc. The filing lists indirect beneficial ownership of 8 shares of common stock as of July 7, 2026, held through Bank of America N.A. and BofA Securities, Inc. The reporting persons note they may have temporarily held additional shares via short-term stock borrowings and expressly disclaim being part of any group for Section 13(d) purposes.